Literature DB >> 19620342

Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.

E Elsa Herdiana Murhandarwati1, Lina Wang, Casilda G Black, Doan Hanh Nhan, Thomas L Richie, Ross L Coppel.   

Abstract

Inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 (MSP1(19)) are a significant component of inhibitory responses in individuals immune to malaria. Nevertheless, conflicting results have been obtained in determining whether this antibody specificity correlates with protection in residents of areas where malaria is endemic. In this study, we examined sera collected from a population of semi-immune individuals living in an area of Vietnam with meso-endemicity during a 6-month period. We used two Plasmodium falciparum parasite lines that express either endogenous MSP1(19) or the homologous region from Plasmodium yoelii to measure the MSP1(19)-specific inhibitory activity. We showed that (i) the level of MSP1(19)-specific inhibitory antibodies was not associated with a delay in P. falciparum infection, (ii) MSP1(19)-specific inhibitory antibodies declined significantly during the convalescent period after infection, and (iii) there was no significant correlation between the MSP1(19)-specific inhibitory antibodies and the total antibodies measured by enzyme-linked immunosorbent assay. These results have implications for understanding naturally acquired immunity to malaria and for the development and evaluation of MSP1(19)-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620342      PMCID: PMC2747923          DOI: 10.1128/IAI.00360-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.

Authors:  L Wang; T L Richie; A Stowers; D H Nhan; R L Coppel
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex.

Authors:  Lina Wang; Lucy Crouch; Thomas L Richie; Doan Hanh Nhan; Ross L Coppel
Journal:  Parasite Immunol       Date:  2003 Aug-Sep       Impact factor: 2.280

3.  Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.

Authors:  Zarifah Hussain Reed; Marie Paule Kieny; Howard Engers; Martin Friede; Sandra Chang; Shirley Longacre; Pawan Malhotra; Weiqing Pan; Carole Long
Journal:  Vaccine       Date:  2008-11-25       Impact factor: 3.641

4.  Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.

Authors:  Chandy C John; Rebecca A O'Donnell; Peter O Sumba; Ann M Moormann; Tania F de Koning-Ward; Christopher L King; James W Kazura; Brendan S Crabb
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

5.  The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia.

Authors:  Patrick H Corran; Rebecca A O'Donnell; Jim Todd; Chairat Uthaipibull; Anthony A Holder; Brendan S Crabb; Eleanor M Riley
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Inhibitory and neutral antibodies to Plasmodium falciparum MSP119 form ring structures with their antigen.

Authors:  Carien Dekker; Chairat Uthaipibull; Lesley J Calder; Matthew Lock; Munira Grainger; William D Morgan; Guy G Dodson; Anthony A Holder
Journal:  Mol Biochem Parasitol       Date:  2004-09       Impact factor: 1.759

7.  Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

Authors:  R A O'Donnell; T F de Koning-Ward; R A Burt; M Bockarie; J C Reeder; A F Cowman; B S Crabb
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

8.  Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum.

Authors:  E Badell; C Oeuvray; A Moreno; S Soe; N van Rooijen; A Bouzidi; P Druilhe
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

9.  Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection.

Authors:  Richard J Pleass; Solabomi A Ogun; David H McGuinness; Jan G J van de Winkel; Anthony A Holder; Jenny M Woof
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

10.  The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.

Authors:  Roseangela I Nwuba; Olugbemiro Sodeinde; Chiaka I Anumudu; Yusuf O Omosun; Alexander B Odaibo; Anthony A Holder; Mark Nwagwu
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  13 in total

1.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

2.  Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria.

Authors:  Josea Rono; Anna Färnert; Daniel Olsson; Faith Osier; Ingegerd Rooth; Kristina E M Persson
Journal:  Infect Immun       Date:  2012-03-05       Impact factor: 3.441

Review 3.  Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

Authors:  Christopher J A Duncan; Adrian V S Hill; Ruth D Ellis
Journal:  Hum Vaccin Immunother       Date:  2012-04-20       Impact factor: 3.452

4.  Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.

Authors:  Luciane M Storti-Melo; Wanessa C Souza-Neiras; Gustavo C Cassiano; Leonardo C Taveira; Antônio J Cordeiro; Vanja S C A Couto; Marinete M Póvoa; Maristela G Cunha; Diana M Echeverry; Andréa R B Rossit; Myriam Arévalo-Herrera; Sócrates Herrera; Ricardo L D Machado
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.

Authors:  Peter D Crompton; Kazutoyo Miura; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta Weiss; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; Chiung-Yu Huang; Ogobara K Doumbo; Louis H Miller; Carole A Long; Susan K Pierce
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

6.  Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection.

Authors:  Josiane Ngoundou-Landji; Roseangela I Nwuba; Chiaka I Anumudu; Alexander B Odaibo; Wenceslas D Matondo Maya; Henrietta O Awobode; Christian M Okafor; Olajumoke A Morenikeji; Adanze Asinobi; Mark Nwagwu; Anthony A Holder; Francine Ntoumi
Journal:  Malar J       Date:  2010-10-18       Impact factor: 2.979

7.  T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines.

Authors:  Kae M Pusic; Caryn N Hashimoto; Axel Lehrer; Charmaine Aniya; David E Clements; George S Hui
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

8.  Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

Authors:  Christopher J A Duncan; Susanne H Sheehy; Katie J Ewer; Alexander D Douglas; Katharine A Collins; Fenella D Halstead; Sean C Elias; Patrick J Lillie; Kelly Rausch; Joan Aebig; Kazutoyo Miura; Nick J Edwards; Ian D Poulton; Angela Hunt-Cooke; David W Porter; Fiona M Thompson; Ros Rowland; Simon J Draper; Sarah C Gilbert; Michael P Fay; Carole A Long; Daming Zhu; Yimin Wu; Laura B Martin; Charles F Anderson; Alison M Lawrie; Adrian V S Hill; Ruth D Ellis
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

9.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

10.  How Should Antibodies against P. falciparum Merozoite Antigens Be Measured?

Authors:  Sriwipa Chuangchaiya; Kristina E M Persson
Journal:  J Trop Med       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.